Navigation Links
Generex Announces Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial
Date:6/12/2013

a proprietary modification that increases its potency.  The studies that were part of this year's ASCO meeting confirm these unique properties.  Dr. Mittendorf was also noted that this vaccine addresses patients with any level of HER2 expression, unlike other HER2-targeted therapies.  Currently, patients with low HER2 expression represent a patient population of significant unmet need (representing 50% of all breast cancers). 

The updates this year built upon interim results of the Company's controlled, randomized Phase IIb clinical trial of AE37 presented at last year's ASCO meeting.  Those presentations demonstrated a clear trend toward reduced relapse in breast cancer patients who had received AE37.  One of the studies this year showed that while some patients developed a hypersensitivity reaction (urticarial response), they appeared to have a stronger all-around immune response to the AE37 vaccine.  Interestingly, no relapses have been observed in this population of patients.  A second presentation demonstrated that repeated AE37 boosters could be safely given to patients to further augment and extend the initial anti-tumor immune response observed with AE37.

The primary efficacy analysis of Phase IIb data from the Antigen Express breast cancer study is expected prior to the end of 2013.  Mark Fletcher, Generex President & Chief Executive Officer, commented: "Based on the outstanding interim results announced at ASCO 2012, we are looking forward to qualitatively similar results with greater statistical robustness when data is evaluated later this year, which will leave Antigen Express well-positioned to secure a partnership for a Phase III trial."  Antigen Express has been encouraged by the US Food and Drug Administration to submit a protocol for the Phase III trial, which the Company is in the process of preparing under the auspices of a Special Protocol Assessment (SPA), whereby the FDA dec
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Generex Touts Pipeline Potential of Antigen Express Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... DIEGO, March 10 Avineuro Pharmaceuticals, Inc. announced today ... a potent and selective small molecule antagonist of 5-HT6 ... I studies are expected to be available in April ... Inc. plans to advance AVN-211 into Phase II clinical ...
... March 9 What if after 100 years of ... conquest of cancer, a small, unheralded, non-profit organization could ... , , Improbable? Perhaps. Impossible? ... garage revolutionized the computer industry? , , ...
Cached Medicine Technology:Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 2Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 3
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value ... US, France, Italy, Germany, Spain and the UK), from ... , The competitive landscape in the B-cell NHL markets ... UK is poised to undergo a dramatic shift during ... B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma ...
(Date:9/1/2014)... Monday 1 September 2014: Daily fruit consumption cuts ... 40%, according to research presented at ESC Congress today ... from the seven year follow-up study of nearly 0.5 ... the more fruit people ate, the more their risk ... ischaemic heart disease (IHD) and stroke, is the leading ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... Get Discount to Switch , ... ... provider of Internet practice management and www.CollaborateMD.com [medical ... program for existing users of Medisoft, Lytec, AltaPoint, Medical Manager ...
... supporters join call for fair & enforceable union,election ground ... is being issued by SEIU United Healthcare Workers - ... System and their supporters,presented an open letter to the ... women religious to help stop the unlawful threats and,intimidation ...
... Minn., Aug. 13 The CHS Foundation,announced today ... the Ralph K.,Morris Foundation,s new Elroy Webster Cooperative ... honorary award to graduate and law,students interested in ... created in memory of Elroy Webster, a,Minnesota farmer ...
... STEN ), a Minneapolis-based diversified business, today reported,results ... June 29,2008. The Company reported a net after-tax ... the third quarter period ended June 29, 2008. ... were $5,035,913, an,increase of 377 percent, or $3,979,309 ...
... cancer,research/programs, DETROIT, Aug. 13 Sean Shearon wanted ... cancer, as well as honor the victims,and survivors of ... 18,marathons in 18 days -- The Victory Walk -- ... programs at the Barbara Ann Karmanos Cancer,Institute, in Detroit. ...
... (August 13, 2008) SAGE, the world,s fifth largest journals ... agreement to publish the Journal of Dental Research ... publication of the International and American Associations for Dental Research ... dedicated to the dissemination of new knowledge and information on ...
Cached Medicine News:Health News:CollaborateMD Offers Upgrade Program to Competitors' Users 2Health News:As Charges Mount, Caregivers and Supporters Call on Sisters of St. Joseph of Orange to Help Stop Unlawful Intimidation of Workers 2Health News:CHS Foundation Helps Launch New Scholarship Fund 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 3Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 4Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 5Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:SAGE to publish Journal of Dental Research beginning in 2009 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: